REPLY
28.9.2021 09:32:12 CEST | Business Wire | Press release
On the 15th of October 2021, Reply will launch the fourth edition of the Reply Cyber Security Challenge, a team-based coding competition open to young professionals and cyber security enthusiasts from all over the world.
This year’s edition will be supported by Intesa Sanpaolo, one of the top banking groups in Europe, and Immersive Labs, the platform empowering businesses to increase, measure and evidence human capability in every part of their cybersecurity.
Intesa Sanpaolo‘s support confirms its commitment to increase education, awareness and training on cybersecurity among young people.
Improving cybersecurity knowledge, skills and judgement is Immersive Labs’ mission and the Reply Cyber Security Challenge represents a new and engaging way to power up people’s cyber capabilities.
The challenge, which in 2020 welcomed more than 10,000 participants from 160 countries gather together in 2,380 teams, aims to put teams (from 2 to 4 players) in competition in a 24-hour marathon, Capture The Flag (CTF) challenge, focusing on the identification of vulnerabilities purposely hidden within software and computer systems.
Developed by Reply's Cyber Security experts, the challenge is comprised of five gaming categories (Coding, Web, Binary, Crypto and Miscellaneous) in which participants will have to try to solve, in the shortest time possible, security problems and riddles of increasing difficulty.
The competition will be held on Friday, October 15 , during the European Cyber Security Month (ECSM) , the European awareness campaign that every year, in October, aims to raise the awareness of citizens, organizations, companies and institutions about the major cyber risks.
The podium will be composed by the top three teams that, at the end of the competition, achieve the highest score and present a report showing the strategies they adopted during the challenge. The final score will be determined by the highest number of hidden flags identified plus a bonus awarded for the quick resolution of the problems.
From today and until October 15th , at the website challenges.reply.com , participants will have the opportunity to register for the challenge for free (by registering their team or joining other players in random teams) and to train in "sandbox" mode on the challenges of previous editions.
The Reply Cyber Security Challenge is also enriched with the Train&Win program. Starting today, teachers and students of more than 16 years will be able to train together with problems to solve in CTF mode on the challenges.reply.com platform and win Reply gadgets for educational purposes. The platform becomes a cyber security gym, with exercises and study materials made available to help prepare for the international competition on October 15th .
The Cyber Security Challenge is part of Reply’s Challenges programme, which aims to target the most innovative trends in coding creativity, cyber security and finance. Since 2018, more than 100,000 people have joined the Reply Challenges community.
°°°
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in designing and implementing solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models supported by big data, cloud computing, digital media and IoT (internet of things). Reply provides consulting, system integration and digital services to organisations across the telecom and media, industry and services, banking and insurance; and public sectors. www.reply.com
Immersive Labs
Immersive Labs is empowering organizations to equip, exercise, and evidence human cyber capabilities. We provide metrics that give security leaders insight into human cyber skills and readiness levels across their organization and improve these through dynamic labs and crisis scenarios that track the threat landscape. Immersive Labs is backed by Goldman Sachs Asset Management, Summit Partners, Insight Partners, Citi Ventures, and Menlo Ventures. Our customers include some of the largest companies in financial services, healthcare, and government, amongst others. For more information on Immersive Labs’ offering, please visit www.immersivelabs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005093/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom